Attenuated viral infections play a crucial role in the development of vaccines, representing a strategy to induce protective immunity without causing severe disease. Attenuation involves reducing the virulence of a pathogen while retaining its ability to stimulate an immune response. In the context of viral vaccines, this typically involves serial passage of the virus in cell culture or animals, leading to adaptations that diminish its pathogenicity in humans. One well-known example is the live attenuated measles vaccine, which has been highly effective in preventing measles outbreaks globally. The process of attenuation often involves mutations in viral genes responsible for replication or virulence, ensuring a safe yet immunogenic vaccine. While live attenuated vaccines offer long-lasting immunity, their use may be restricted in certain populations, such as immunocompromised individuals, due to potential risks of reversion to virulence. The development and optimization of attenuated vaccines require a deep understanding of viral biology and host-pathogen interactions. Researchers meticulously balance the attenuation process to ensure safety and efficacy. Advances in genetic engineering techniques have enabled the creation of recombinant attenuated vaccines, where specific genes associated with virulence are modified or deleted. Despite their success, continuous monitoring is essential to address concerns about vaccine stability, potential reversion, and unforeseen consequences.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : When acute EBV mimics HIV: A case of false positive p24 antigen and low-level HIV antibody reactivity
Smriti Chaudhary, Imperial College Healthcare NHS Trust, United Kingdom
Title : OnePeru: Peruvian bioinformatics platform to contribute to the fight against antimicrobial resistance
Pool Marcos Carbajal, University of San Martin de Porres, Peru
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain